Adaptive Biotechnologies Corp. (ADPT), Saturday, announced new encouraging data, highlighting advances in measurable residual disease, previously termed minimal residual disease, testing with clonoSEQ and its impact on blood cancer treatment decisions.
clonoSEQ is an FDA-cleared test used to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia, and blood or bone marrow from patients with chronic lymphocytic leukemia.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com